Upregulation of connexin43 gap junctions between neointimal smooth muscle cells.
Increased expression of connexin43 gap junctions in smooth muscle cells (SMC) is implicated in the response to primary arterial injury and in the early stages of human coronary atherosclerosis, but the relevance of these findings to restenosis is unknown. Here we investigated the expression of connexin43 gap junctions in restenotic aortas of cholesterol-fed double injured rabbits. Immunofluorescence confocal microscopy was used to evaluate temporal and spatial expression patterns and to characterize the major expressing cell type. Parallel studies were conducted by electron microscopy, in situ hybridization and Northern blot analysis. Connexin43 gap junctions- and connexin43 mRNA-expressing cells were abundant in the media of non-injured control aorta. Following primary injury and 6 weeks cholesterol diet, connexin43 gap junctions were found distributed throughout the primary intimal layer; although medial expression was reduced, the overall mRNA expression level remained similar to that of non-injured controls. After secondary injury, no major change in distribution pattern of connexin43 gap junctions occurred up to day 10, when marked neointimal labeling was observed. This overall pattern persisted, though with some diminution, at later stages. On the mRNA level total connexin43 mRNA expression declined to about 40% of control values within 4 days after secondary injury (P < 0.05), but subsequently increased four-fold, attaining levels double that of non-injured controls in the 10-day group (P < 0.005 versus control and 4 days). At later stages mRNA expression levels returned to values similar to those of non-injured controls. At all stages, connexin43 gap junctions were localized to the SMC, not to macrophages. We conclude that the enhanced gap junction formation may contribute to the coordination of the response of SMC after secondary injury, particularly in the early phase of restenosis.
Plenz
Gabriele
G
Institute for Arteriosclerosis Research, Münster, Germany. plenz@uni-muenster.de
Ko
Yu-shien
YS
Yeh
Hung-I
HI
Eschert
Heike
H
Sindermann
Jürgen R
JR
Dorszewski
Anja
A
Hofnagel
Oliver
O
Robenek
Horst
H
Breithardt
Günther
G
Severs
Nicholas J
NJ
D000818:Animals; D001012:Aorta, Abdominal / Q000293:injuries / Q000648:ultrastructure; D001024:Aortic Valve Stenosis / Q000378:metabolism* / Q000473:pathology; D001161:Arteriosclerosis / Q000378:metabolism* / Q000473:pathology; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D018031:Connexin 43 / Q000235:genetics / Q000378:metabolism* / Q000648:ultrastructure; D004195:Disease Models, Animal; D018450:Disease Progression; D017629:Gap Junctions / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D015870:Gene Expression / Q000187:drug effects; D008264:Macrophages / Q000378:metabolism / Q000473:pathology; D008297:Male; D018613:Microscopy, Confocal; D032389:Myocytes, Smooth Muscle / Q000378:metabolism* / Q000473:pathology / Q000648:ultrastructure; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D011817:Rabbits; D017539:Tunica Intima / Q000378:metabolism* / Q000473:pathology; D015854:Up-Regulation; D014654:Vascular Patency
D002791:Cholesterol, Dietary; D018031:Connexin 43; D012333:RNA, Messenger